Inflammatix
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Inflammatix sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Inflammatix: 5 sponsored US clinical trials, 1 recruiting.
Inflammatix sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. The most-studied condition in this pipeline is Sepsis, with 2 trials.
Upper-quartile sponsor footprint
Inflammatix sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
NCT06637904
Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial
NCT04414189
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
NCT04094818
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
NCT03744741
Collection of Clinical Specimens From Volunteers for Assay Development
NCT03606382
Therapeutic Areas
What is open in the Inflammatix pipeline
1 recruiting of 5 indexed (20% open); 4 completed (80%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Sepsis (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Inflammatix: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Inflammatix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Inflammatix page
5 registered trials is a research-attention snapshot, not an endorsement of Inflammatix or any single study.
- 1 of Inflammatix's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sepsis is the condition Inflammatix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sepsis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Inflammatix pipeline card: 5 registered trials from official public datasets.Report a data error.